MedTrace Logo

Treatment of Apathy in Alzheimer's Disease With Modafinil

NCT01172145 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2011-03-04

Study results available
· View outcomes & findings →

Summary

This study examined the effects of modafinil on apathetic symptomatology, performance of activities of daily living (ADLs) and caregiver burden in individuals with Alzheimer's disease (AD).

Conditions

Interventions

DRUG

Modafinil

100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks

DRUG

Placebo

100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Cephalon

    collaborator INDUSTRY

  • Brown University

    lead OTHER

Principal Investigators

  • Laura L Frakey, Ph.D. · Memorial Hospital of Rhode Island

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-07-31
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01172145 on ClinicalTrials.gov